Literature DB >> 22438471

Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.

Colin S Cunningham1, Martin A Javors, Lance R McMahon.   

Abstract

This study examined mechanisms by which nicotine (1.78 mg/kg base s.c.) produces discriminative stimulus effects in rhesus monkeys. In addition to nicotine, various test compounds were studied including other nicotinic acetylcholine receptor agonists (varenicline and cytisine), antagonists [mecamylamine and the α4β2 receptor-selective antagonist dihydro-β-erythroidine (DHβE)], a nicotinic acetylcholine receptor antagonist/indirect-acting catecholamine agonist (bupropion), and non-nicotinics (cocaine and midazolam). Nicotine, varenicline, and cytisine dose-dependently increased drug-lever responding; the ED(50) values were 0.47, 0.53, and 39 mg/kg, respectively. Bupropion and cocaine produced 100% nicotine-lever responding in a subset of monkeys, whereas mecamylamine, DHβE, and midazolam produced predominantly vehicle-lever responding. The training dose of nicotine resulted in 1128 ng/ml cotinine in saliva. Mecamylamine antagonized the discriminative stimulus effects of nicotine and varenicline, whereas DHβE was much less effective. Nicotine and varenicline had synergistic discriminative stimulus effects. In monkeys responding predominantly on the vehicle lever after a test compound (bupropion, cocaine, and midazolam), that test compound blocked the nicotine-discriminative stimulus, perhaps reflecting a perceptual-masking phenomenon. These results show that nicotine, varenicline, and cytisine produce discriminative stimulus effects through mecamylamine-sensitive receptors (i.e., nicotinic acetylcholine) in primates, whereas the involvement of DHβE-sensitive receptors (i.e., α4β2) is unclear. The current nicotine-discrimination assay did not detect a difference in agonist efficacy between nicotine, varenicline, and cytisine, but did show evidence of involvement of dopamine. The control that nicotine has over choice behavior can be disrupted by non-nicotinic compounds, suggesting that non-nicotinics could be exploited to decrease the control that tobacco has over behavior.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438471      PMCID: PMC3362877          DOI: 10.1124/jpet.112.193078

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  36 in total

1.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

2.  Measuring nicotine intake in population surveys: comparability of saliva cotinine and plasma cotinine estimates.

Authors:  Martin J Jarvis; Paola Primatesta; Bob Erens; Colin Feyerabend; Andrew Bryant
Journal:  Nicotine Tob Res       Date:  2003-06       Impact factor: 4.244

3.  Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.

Authors:  Kerri A Schoedel; Edward M Sellers; Roberta Palmour; Rachel F Tyndale
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

4.  Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement.

Authors:  Cecilia Gotti; Stefania Guiducci; Vincenzo Tedesco; Silvia Corbioli; Lara Zanetti; Milena Moretti; Alessio Zanardi; Roberto Rimondini; Manolo Mugnaini; Francesco Clementi; Christian Chiamulera; Michele Zoli
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

Review 5.  Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.

Authors:  Tanya L Wallace; Richard H P Porter
Journal:  Biochem Pharmacol       Date:  2011-07-02       Impact factor: 5.858

6.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

7.  Evidence for perceptual masking of the discriminative morphine stimulus.

Authors:  D V Gauvin; A M Young
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice.

Authors:  J Gommans; I P Stolerman; M Shoaib
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

9.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

10.  An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine.

Authors:  J L Wilkinson; F I Carroll; R A Bevins
Journal:  J Psychopharmacol       Date:  2009-03-20       Impact factor: 4.153

View more
  20 in total

1.  Nicotine as a discriminative stimulus for ethanol use.

Authors:  Brett C Ginsburg; Simon A Levy; R J Lamb
Journal:  Drug Alcohol Depend       Date:  2017-11-21       Impact factor: 4.492

2.  Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys.

Authors:  Megan J Moerke; Lance R McMahon
Journal:  Drug Dev Ind Pharm       Date:  2019-02-22       Impact factor: 3.225

3.  Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms.

Authors:  Colin S Cunningham; Megan J Moerke; Lance R McMahon
Journal:  Pharmacol Biochem Behav       Date:  2019-02-06       Impact factor: 3.533

4.  Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.

Authors:  Rajeev I Desai; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2015-03-06       Impact factor: 7.853

5.  Methamphetamine-like discriminative-stimulus effects of nicotinic agonists.

Authors:  Rajeev I Desai; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2014-01-03       Impact factor: 4.030

6.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

7.  Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.

Authors:  Colin S Cunningham; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2013-03-14       Impact factor: 4.530

8.  The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.

Authors:  Megan J Moerke; Andy Z X Zhu; Rachel F Tyndale; Martin A Javors; Lance R McMahon
Journal:  Neuropharmacology       Date:  2016-12-08       Impact factor: 5.250

9.  Effects of the nicotinic acetylcholine receptor antagonist mecamylamine on the discriminative stimulus effects of cocaine in male rhesus monkeys.

Authors:  Matthew L Banks
Journal:  Exp Clin Psychopharmacol       Date:  2014-02-17       Impact factor: 3.157

10.  Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.

Authors:  Emily M Jutkiewicz; Kenner C Rice; F Ivy Carroll; James H Woods
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.